SANUWAVE HEALTH DL -,001 Aktie

Sanuwave Health reported an adjusted loss of $0.08 per share and revenue of $9.74 million for Q2 2026, both below consensus estimates, driven by a steep decline in UltraMIST system sales (-34% y/y). The recurring applicator business remained robust: applicator revenue rose to $7.3 million and unit volumes reached a record high. Management sees significant cannibalization from used devices and withdrew its full-year revenue guidance due to uncertainty around planned changes to Medicare reimbursement. The company emphasizes operational discipline and is monitoring market reactions to the final CMS rule expected in early November. » Más en de.investing.com

Sanuwave expects preliminary revenue for Q2 2026 of $9.6 to $9.8 million, above its revised guidance range of $8.5 to $9.5 million. That represents a decline of about 3–5% versus Q2 2025 ( $10.1 million). CEO Morgan Frank attributes the development to pressures in the customer base and the sale of used Ultramist systems; the company has launched a trade-in program and saw record sales of disposable applicators. The preliminary figures are based on an initial management review and will be finalized in August. » Más en de.investing.com

SANUWAVE reported a Q4 2025 revenue record of $13.4 million (up 30% year‑over‑year) and adjusted EBITDA of $4.8 million; full‑year revenue was $44.1 million, a 35% increase. Management blamed industry disruption from CMS reimbursement cuts for skin substitutes for near‑term customer and patient count pressure but said UltraMIST and code 97610 were not materially affected and early demand pickup and new reseller partnerships signal recovery. The company ended Q4 with 1,292 active systems, sold 624 systems in 2025, took charges related to sunsetting product lines and sales‑tax restatements, and guided Q1 revenue to $9.6–$10.3 million while targeting mid‑teens to mid‑20s percentage revenue growth for the year. » Más en finance.yahoo.com